|1.||Beliaev, D L: 5 articles (01/2007 - 01/2002)|
|2.||Lepekha, L N: 2 articles (01/2004 - 01/2003)|
|3.||Gedymin, L E: 2 articles (01/2004 - 01/2003)|
|4.||Babaiants, A A: 2 articles (01/2004 - 01/2003)|
|5.||Erokhin, V V: 2 articles (01/2004 - 01/2003)|
|6.||Kuznetsov, V P: 2 articles (01/2003 - 01/2002)|
|7.||Gracheva, M P: 1 article (01/2007)|
|8.||Gabaraev, A S: 1 article (01/2007)|
|9.||Maliev, B M: 1 article (01/2007)|
|10.||Mishin, V Iu: 1 article (01/2004)|
01/01/1995 - "[The use of leukinferon in treating measles in adult patients]."
01/01/1995 - "Leukinferon, a wide-spectrum immunocorrective drug, was used to improve the efficacy of treatment of adult patients with measles; besides alpha-interferon, it contains other cytokines of the first phase of immune response. "
04/01/1998 - "Leukinferon administered before infection affects the development of a Hymenolepis nana population in the murine intestine: in rodents, its defective forms predominate over mature ones. "
01/01/1993 - "[The combined therapy of patients with gonorrheal-chlamydial urogenital infections by leukinferon immunocorrection]."
09/01/1990 - "[Clinical and laboratory effect of leukinferon in purulent infections]."
01/01/1989 - "[Leukinferon in the combined therapy of infection in neonates and infants]."
03/01/1993 - "major a prolongation of the incubation period and a more benign course of the infection were observed after a course of leukinferon injections."
01/01/2004 - "Experiments on 140 CBA and C57BL/6 mice and studies of 163 patients with acute pulmonary tuberculosis have indicated that leukinferon has a immunomodulating effect on morphological reactions in the lung and on the clinical course of the disease. "
01/01/2004 - "[Leukinferon in combined therapy for acute pulmonary tuberculosis]."
01/01/2004 - "[Leukinferon immunomodulation in pulmonary tuberculosis]."
01/01/2007 - "The local administration of leukinferon reduces the time of cure of specific and nonspecific bronchial diseases in patients with pulmonary tuberculosis who isolate DR MBT strains, thus promoting the enhanced efficiency of treatment in reducing the times of bacterial isolation and decay cavity closure and the length of hospital stay."
01/01/2007 - "Inclusion of the immunomodulator leukinferon into the combined therapy of patients with pulmonary tuberculosis complicated by bronchial diseases contributes to the elevation of BAL cell production of alpha and gamma-interferons, reduces the generation of active oxygen forms in the BAL phagocytes and brush biopsy specimens, and increases the levels of immunoglobulins in BAL. "
|4.||Wounds and Injuries (Trauma)
01/01/2004 - "Clinical and cytochemical study of the wound exudate neutrophilic granulocytes (NG) in patients with maxillofacial phlegmons treated traditionally and with leukinferon (immunomodulator) added to basic therapy demonstrated a positive clinical effect and pronounced stimulation of NG in the patients treated with leukinferon. "
01/01/2004 - "[Leukinferon-induced changes in cytochemical parameters of the wound exudate neutrophilic granulocyte nucleus and cytoplasm in patients with maxillofacial phlegmons]."
01/01/1999 - "[Use of leukinferon for prophylaxis of pyogenic complications in victims with thoracic wounds]."
01/01/1999 - "36 of them after surgery to prevent pyogenous complications received 5 injections of leukinferon (test group); 95 patients who were not treated by leukinferon made up control group comparable with the test group by sex, age and character of wounds. "
|1.||Interferon-alpha (Interferon Alfa)
|5.||Arachidonic Acid (Vitamin F)
|9.||Reactive Oxygen Species (Oxygen Radicals)
|10.||Erythromycin Ethylsuccinate (E-Mycin E)